Skip to main content
TELCON RF PHARMACEUTICAL. Inc. logo

TELCON RF PHARMACEUTICAL. Inc. — Investor Relations & Filings

Ticker · 200230 ISIN · KR7200230001 KO Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2024-11-11 Major Shareholding Noti…
Country KR South Korea
Listing KO 200230

About TELCON RF PHARMACEUTICAL. Inc.

http://www.telcon-rf.com

TELCON RF PHARMACEUTICAL. Inc. operates across two primary business segments: radio frequency (RF) components and pharmaceuticals. The RF division specializes in the development, manufacturing, and global sale of components for wireless communication equipment. Its main products include RF coaxial connectors, cable assemblies, coaxial couplers, and distributors. The pharmaceutical and biotechnology division is engaged in the development and sale of medicinal products.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. It details changes in shareholding (specifically convertible bonds) by Sangsangin Savings Bank and its affiliate in Telcon RF Pharmaceutical. This type of filing is a regulatory requirement for entities crossing significant ownership thresholds, which falls under the 'Major Shareholding Notification' category.
2024-11-11 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a formal regulatory filing from Telcon RF Pharmaceutical regarding the 'Decision to Acquire Shares and Securities of Another Corporation' (타법인주식및출자증권취득결정). It details the acquisition of shares in Abion Inc. through a third-party allocation capital increase. This type of corporate action, involving strategic investment and equity acquisition, is classified under M&A Activity (TAR) as it pertains to the acquisition of equity interests in another entity.
2024-11-11 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Extraordinary General Meeting' (제26기 임시주주총회 소집통지서) for Telcon RF Pharmaceutical. It includes the meeting agenda, voting procedures, electronic voting instructions, and management reference materials (such as director activities and business overviews). This type of document is a standard proxy statement/information statement sent to shareholders to solicit votes for an upcoming meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2024-11-07 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy/Voting Rights). It contains detailed information regarding a shareholder meeting, including the purpose of the meeting (stock consolidation), proxy solicitation details, electronic voting procedures, and the agenda. This document is a formal proxy solicitation statement provided to shareholders to request their votes, which falls under the 'Proxy Solicitation & Information Statement' category.
2024-11-07 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Telcon RF Pharmaceutical) regarding the 'Acquisition of Convertible Bonds before Maturity'. This type of filing details changes to the company's capital structure and debt obligations, specifically the buyback of convertible bonds. It fits the 'Capital/Financing Update' category as it relates to financing activities and changes in debt instruments.
2024-10-31 Korean
전환가액의조정
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from Telcon RF Pharmaceutical regarding the adjustment of the conversion price for convertible bonds (19th series) due to a decline in market price. This type of disclosure, which details changes to the terms of existing financial instruments (specifically conversion price adjustments), falls under the category of capital and financing updates as it directly impacts the company's capital structure and potential future share dilution.
2024-10-31 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.